Refine by
Cancer Patient Articles & Analysis: Older
85 articles found
The integration of tumor models in the development of customized ADCs is a game-changer in breast cancer research. By utilizing tumor models that closely resemble patient tumors, researchers can evaluate the effectiveness of ADCs in a context that reflects the actual disease. ...
Precision-Cut Lung Slices (PCLS) have emerged as a innovative ex vivo model that allows researchers to explore deep into lung physiology, disease mechanisms, and pharmacological responses. By offering a unique combination of biological complexity and controlled experimental conditions, PCLS serve as a critical bridge between the limitations of traditional in vitro cell cultures and the ...
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of ...
The emergence of chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of certain cancers, providing a promising targeted approach to eliminate cancer cells. ...
Early detection and regular screening are pivotal in perfecting outcomes for patients with breast cancer. Why Breast Cancer Occurs Breast cancer occurs when normal cells in the breast tissue suffer gene mutations that cause them to grow and multiply in an uncontrolled manner. ...
Imagine a world where diseases like cancer, Alzheimer's, and Parkinson's could be diagnosed and treated at the molecular level, long before symptoms even appear. ...
ByMatexcel
Monitor the effectiveness of cancer therapies Luminex technology can be used to monitor the impact of cancer treatments on the cytokine profile of a patient. ...
Monitor the effectiveness of cancer therapies Luminex technology can be used to monitor the impact of cancer treatments on the cytokine profile of a patient. ...
By encapsulating drugs within these microspheres, pharmaceutical companies are able to improve patient compliance, reduce dosing frequency, and enhance therapeutic outcomes. ...
Understanding the mechanisms underlying CDH1 loss and its impact on cancer progression is crucial for developing targeted therapies and improving patient outcomes. ...
Understanding Clonality Analysis Clonality refers to the origin of a cell population from a single 'parent' or progenitor cell through asexual reproduction or division. This concept is vital in cancer studies as it helps track the development of tumor cells from a single mutated cell. Clonality analysis is thus essential in understanding the evolution and the spread of ...
Patients at risk for invasive fungal infections include severely ill patients, immunosuppressed patients, patients after surgery, and patients using central venous catheters. ...
The majority of patients with metastatic breast cancer (MBC) have hormone receptor-positive HER2-negative disease. ...
Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. ...
Recently, in a research report entitled "Oncogenic CDK13 mutations impede nuclear RNA surveillance" published in Science, scientists from Howard Hughes Medical Institute and other institutions discovered a new type of mechanism that affects the occurrence of melanoma, providing broad and important implications for the treatment of various cancer patients. In ...
Trastuzumab Emtansine (T-DM1) Trastuzumab Emtansine (T-DM1) is the first ADC drug approved for breast cancer. As early as 2013 and 2019, it has been approved by FDA for the adjuvant therapy of HER2-positive advanced breast cancer patients who have received trastuzumab and paclitaxel chemotherapy and HER2-positive early breast ...
In general, the incidence of ADA of ADCs is less in patients targeting hematologic cancer than in patients targeting solid cancer; Most ADA is specific to the monoclonal antibody domain of the ADC. Furthermore, in most patients, the hapten-like structure of these ADCs does not generate any more risk of an immune ...
Medical History Jane is a 40-year-old, married mother of two teenage boys. She teaches at the local elementary school and has been in good health for most of her life. She has no surgical history. Her most severe ailment up to this point has been the flu at age 27. Her students are first-graders; they are often difficult to control. She also experiences the normal stresses of raising ...
In addition, more than 100 ADC drug candidates are currently under clinical investigation. The new class of cancer drugs, known as "biological missiles," usher in a new era of targeted cancer therapy. ...
In Sun’s research, label-free quantification was applied to systematically compare the protein profiling in saliva and serum exosomes from healthy subjects and lung cancer patients, and potential candidates were discovered as biomarkers for lung cancer. ...